Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
July 12, 2024

Leqembi gains approval for Alzheimer’s treatment in Israel

BioArctic's partner Eisai has announced that Leqembi, has received approval in Israel for the treatment of Alzheimer's disease (AD), specifically for patients with mild cognitive impairment or mild dementia, the same stages targeted in clinical trials.

Israel becomes the sixth territory to endorse the drug for Alzheimer's treatment after the US, Japan, China, South Korea, and Hong Kong. Credit: TioNegro14 from Pixabay.